1. Home
  2. HOWL vs GNLX Comparison

HOWL vs GNLX Comparison

Compare HOWL & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOWL
  • GNLX
  • Stock Information
  • Founded
  • HOWL 2017
  • GNLX 2001
  • Country
  • HOWL United States
  • GNLX United States
  • Employees
  • HOWL N/A
  • GNLX N/A
  • Industry
  • HOWL Biotechnology: Pharmaceutical Preparations
  • GNLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • HOWL Health Care
  • GNLX Health Care
  • Exchange
  • HOWL Nasdaq
  • GNLX Nasdaq
  • Market Cap
  • HOWL 87.4M
  • GNLX 85.0M
  • IPO Year
  • HOWL 2021
  • GNLX 2023
  • Fundamental
  • Price
  • HOWL $1.51
  • GNLX $5.46
  • Analyst Decision
  • HOWL Strong Buy
  • GNLX Strong Buy
  • Analyst Count
  • HOWL 2
  • GNLX 4
  • Target Price
  • HOWL $9.50
  • GNLX $18.25
  • AVG Volume (30 Days)
  • HOWL 253.4K
  • GNLX 382.1K
  • Earning Date
  • HOWL 03-06-2025
  • GNLX 03-31-2025
  • Dividend Yield
  • HOWL N/A
  • GNLX N/A
  • EPS Growth
  • HOWL N/A
  • GNLX N/A
  • EPS
  • HOWL N/A
  • GNLX N/A
  • Revenue
  • HOWL $3,386,000.00
  • GNLX $8,000.00
  • Revenue This Year
  • HOWL N/A
  • GNLX N/A
  • Revenue Next Year
  • HOWL $34.17
  • GNLX N/A
  • P/E Ratio
  • HOWL N/A
  • GNLX N/A
  • Revenue Growth
  • HOWL N/A
  • GNLX N/A
  • 52 Week Low
  • HOWL $1.26
  • GNLX $1.60
  • 52 Week High
  • HOWL $8.19
  • GNLX $8.67
  • Technical
  • Relative Strength Index (RSI)
  • HOWL 56.19
  • GNLX 75.73
  • Support Level
  • HOWL $1.28
  • GNLX $4.10
  • Resistance Level
  • HOWL $1.57
  • GNLX $5.89
  • Average True Range (ATR)
  • HOWL 0.11
  • GNLX 0.58
  • MACD
  • HOWL 0.03
  • GNLX 0.16
  • Stochastic Oscillator
  • HOWL 73.59
  • GNLX 84.17

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Share on Social Networks: